Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
EGFRの阻害剤およびその使用法
Document Type and Number:
Japanese Patent JP7335275
Kind Code:
B2
Abstract:
The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Inventors:
Nathaniel S. Gray
Doris de Clerc
Jebon Jean
Pasi Jeanne
Cilic To
Michael Ek
Eunyoung Park
David Hepner
Application Number:
JP2020566547A
Publication Date:
August 29, 2023
Filing Date:
February 20, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Dana Farber Cancer Institute, Incorporated
International Classes:
C07D243/38; A61K31/551; A61K45/00; A61P35/00; A61P43/00; C07D401/06; C07D401/10; C07D401/14; C07D403/04; C07D403/06; C07D403/10; C07D403/14; C07D417/06; C07D417/14; C07D471/04
Domestic Patent References:
JP2015205911A
JP2012511054A
JP2021514400A
Foreign References:
WO2015196072A2
WO2017177092A1
WO2014160430A1
US20070105835
WO2016201370A1
WO2009124399A1
Other References:
Praveen Kumar, Chintakunta et al.,Synthesis and biological evaluation of 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one structural derivatives as anti-cancer and apoptosis inducing agents,European Journal of Medicinal Chemistry,(2016), 108, 674-686,2016年
Mastalerz, Harold et al.,Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases,Bioorganic & Medicinal Chemistry Letters,2007年,(2007), 17(10), 2828-2833
Attorney, Agent or Firm:
Yasuhiko Murayama
Shinya Mihiro
Tatsuhiko Abe